Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – Here’s Why

Pharming Group (NASDAQ:PHAR) saw unusually-strong trading volume on Friday . Approximately 2,626 shares were traded during mid-day trading, a decline of 46% from the previous session’s volume of 4,869 shares.The stock last traded at $8.72 and had previously closed at $8.30.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a report on Thursday.

Pharming Group Stock Up 5.1 %

The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40. The company has a 50-day moving average of $8.03 and a two-hundred day moving average of $8.56. The company has a market capitalization of $591.48 million, a P/E ratio of -45.89 and a beta of 0.15.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The firm had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. During the same period last year, the firm posted $0.02 earnings per share. On average, research analysts predict that Pharming Group will post -0.15 EPS for the current year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR) by 32.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.